Singapore’s Kexin vaccine “does not count” in the future still need to be screened as required

Singapore’s Ministry of Health said on July 7 that the country currently only recognizes the effectiveness of the Pfizer/BNT and Moderna vaccines, while the Sinovac vaccine is not recognized and therefore will not be included in the statistical list of those who have received the vaccine, and those who have only received the Sinovac vaccine must continue to be screened in accordance with regulations if they wish to participate in certain activities or enter certain venues.

According to Reuters, Singapore’s Ministry of Health said in an emailed statement that “national vaccine figures will only reflect those vaccinated under the National Vaccination Programme” and that Singapore currently only includes those who have received the Modena and Pfizer/BNT vaccines.

China’s Kexing vaccine, which is not part of Singapore’s national vaccination program, has said it is still waiting for key information from the company.

The Kexing vaccine has a clinical protection of just over 50%, and its effectiveness is entirely up to chance. Both Indonesia and Thailand have reported the death of health care workers who contracted the disease after being fully vaccinated with the Coxin vaccine. In Indonesia, 26 frontline physicians have died of the disease so far in June. Among the 26 physicians who died in the battle, at least 10 have received two doses of China’s Kexing vaccine, and the country has recently reported that more than 350 health care workers have been infected with the more infectious Delta mutant virus after receiving the Kexing vaccine, which has once again raised questions about the effectiveness of the vaccine made in China.

The Singaporean government announced on June 16 that 24 private medical institutions could administer 200,000 doses of the Coxin vaccine, which arrived in Singapore in February, through the Special Access Route (SAR). The Chinese official media took the opportunity to make a “big internal propaganda”, claiming that the public response to Singapore’s Koxin vaccination was overwhelming and demand exceeded supply, but only about 17,000 doses have been administered so far, and most of the Koxin vaccine recipients are Chinese nationals who believe that the Chinese-made vaccine will make it easier for them to return to their home countries without being placed in quarantine.

Kenneth Mak, director of medical services at Singapore’s Ministry of Health, warned in June that the Coxin vaccine could cause a breach in epidemic prevention, according to other countries that have administered the Coxin vaccine and have since seen confirmed cases.